利肺片联合异丙托溴铵治疗支气管哮喘慢性持续期的临床研究

目的探讨利肺片联合异丙托溴铵气雾剂治疗支气管哮喘慢性持续期的临床疗效。方法选择2015年1月—2017年12月武汉市红十字会医院收治的支气管哮喘患者105例为研究对象,按随机数字表法随机分为对照组(52例)和治疗组(53例)。对照组雾化吸入异丙托溴铵气雾剂,2掀/次,2次/d。治疗组在对照组治疗的基础上饭后30 min口服利肺片,2片/次,3次/d。两组均连续治疗14 d。观察两组的临床疗效,比较两组的肺功能指标和血清因子水平。结果治疗后,对照组和治疗组的总有效率分别为84.62%、96.23%,两组比较差异有统计学意义(P0.05)。治疗后,两组用力肺活量(FVC)、1秒用力呼气容积(FEV1)和最大呼气流速(PEF)均显著升高,同组治疗前后比较差异有统计学意义(P0.05);且治疗组肺功能指标明显高于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组血清白细胞介素17(IL-17)、白三烯B4(LTB4)、中性粒细胞(PMN)均显著下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组血清因子水平明显低于对照组,两组比较差异具有统计学意义(P0.05)。结论利肺片联合异丙托溴铵气雾剂治疗支气管哮喘慢性持续期具有较好的临床疗效,能改善肺功能,调节IL-17、LTB4水平,降低PMN计数,安全性较好,具有一定的临床推广应用价值。

Clinical study on Lifei Tablets combined with ipratropium bromide in treatment of chronic persistent bronchial asthma

Objective To investigate the clinical efficacy of Lifei Tablets combined with Ipratropium Bromide Aerosol in treatment of chronic persistent bronchial asthma. Methods Patients (105 cases) with bronchial asthma in Wuhan Red Cross Hospital from January 2015 to December 2017 were randomly divided into the control group (52 cases) and the treatment group (53 cases). Patients in the control group were atomization inhalation administered with Ipratropium Bromide Aerosol, 2 presses/time, twice daily. Patients in the treatment group were po administered with Lifei Tablets on the basis of the control group at 30 minutes after meals, 2 tablets/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and pulmonary function indexes and serum factor levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 84.62% and 96.23%, respectively, and there was difference between two groups (P<0.05). After treatment, FVC, FEV1, and PEF in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the pulmonary function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, IL-17, LTB4, PMN in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serum factor levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Lifei Tablets combined with Ipratropium Bromide Aerosol has clinical curative effect in treatment of chronic persistent bronchial asthma, can improve lung function, regulate the levels of IL-17 and LTB4, and reduce PMN count, with good safety, which has a certain clinical application value.